Clenbuterol
Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia
CuraSen Therapeutics, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Mild Cognitive Impairment, Lewy Body Dementia, Parkinson's Disease Rapid Eye Movement Sleep Behavior Disorder, Parkinson's Disease Dementia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
NADOLOL CuraSen Therapeutics, Inc. | Phase 2 | B |
Same molecule, other indications
Clenbuterol is also rated in:
glycogen storage disease due to acid maltase deficiency, late-onsetDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →